"studyEstimands","bcCategories","uuid:ID","documentVersion","name","studyDesignRationale","id","label","studyInvestigationalInterventions","description"
"[]","[]","7ef57530-b41c-407f-9d6f-950bb6aa57da","","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","","[]","The main design for the study"
